TY - JOUR
T1 - The Role of TCF7L2 in Type 2 Diabetes
AU - Del Bosque-Plata, Laura
AU - Martínez-Martínez, Eduardo
AU - Espinoza-Camacho, Miguel Ángel
AU - Gragnoli, Claudia
N1 - Funding Information:
Funding. E.M.-M. is supported by Consejo Nacional de Ciencia y Tecnología (CONACYT) (258589). C.G. is supported by National Institute of Child Health and Human Development grant 5R01HD086911-02 (Principal Investigator). Duality of Interest. No potential conflicts of interest relevant to this article were reported.
Publisher Copyright:
© 2021 by the American Diabetes Association. Readers may use this article.
PY - 2021/6
Y1 - 2021/6
N2 - TCF7L2 is the most potent locus for type 2 diabetes (T2D) risk and the first locus to have been robustly re-ported by genomic linkage studies. TCF7L2 is a transcription factor that forms a basic part of the Wnt signaling pathway. This gene has highly conserved sequence regions that correspond to functional domains. The association of TCF7L2 with T2D is one of the most powerful genetically discovered in studies of complex diseases, as it has been consistently replicated in multiple populations with diverse genetic origins. The mechanisms over which TCF7L2 exerts its effect on T2D are still not well understood. In this article, we describe the main molecular mechanisms of how TCF7L2 is related to T2D. TCF7L2 variants associated with T2D risk exert an influence on the initial therapeutic success of the hypoglycemic oral agent sulfonylurea. Thus, it is important to know whether there are other TCF7L2 variants associated with T2D that can influence treatment with oral hypoglycemic agents. Resequencing of the TCF7L2 gene in diverse ethnic groups is required to reveal com-mon and rare variations and their role in different pathologies and in adverse reactions to drugs. Identification of TCF7L2-susceptibility disease variants will permit, at a given moment, offering of therapies to patients according to their genotype.
AB - TCF7L2 is the most potent locus for type 2 diabetes (T2D) risk and the first locus to have been robustly re-ported by genomic linkage studies. TCF7L2 is a transcription factor that forms a basic part of the Wnt signaling pathway. This gene has highly conserved sequence regions that correspond to functional domains. The association of TCF7L2 with T2D is one of the most powerful genetically discovered in studies of complex diseases, as it has been consistently replicated in multiple populations with diverse genetic origins. The mechanisms over which TCF7L2 exerts its effect on T2D are still not well understood. In this article, we describe the main molecular mechanisms of how TCF7L2 is related to T2D. TCF7L2 variants associated with T2D risk exert an influence on the initial therapeutic success of the hypoglycemic oral agent sulfonylurea. Thus, it is important to know whether there are other TCF7L2 variants associated with T2D that can influence treatment with oral hypoglycemic agents. Resequencing of the TCF7L2 gene in diverse ethnic groups is required to reveal com-mon and rare variations and their role in different pathologies and in adverse reactions to drugs. Identification of TCF7L2-susceptibility disease variants will permit, at a given moment, offering of therapies to patients according to their genotype.
UR - http://www.scopus.com/inward/record.url?scp=85111793727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111793727&partnerID=8YFLogxK
U2 - 10.2337/DB20-0573
DO - 10.2337/DB20-0573
M3 - Article
C2 - 34016596
AN - SCOPUS:85111793727
VL - 70
SP - 1220
EP - 1228
JO - Diabetes
JF - Diabetes
SN - 0012-1797
IS - 6
ER -